98%
921
2 minutes
20
Keratinases are becoming biotechnologically important since they have shown potential in hydrolysis of recalcitrant keratins with highly rigid and strongly cross-linked structures. However, the large-scale application of keratinases has been limited by the inefficient expression level and low enzyme activity. In this work, we employed pro-peptide engineering and saturation mutagenesis to construct excellent keratinase variants with improved activities. It turned out that amino acid substitutions at the pro-peptide cleavage site (P1) could accelerate the release of active mature enzymes, resulting in a 3-fold activity increase. Eighteen sites of the pro-peptide area were targeted for codon mutagenesis, and a multisite saturation mutagenesis library of the six potential sites was generated, achieving a significant improvement of keratinase activity from 179 to 1114 units/mL. Also, the mutants exhibited alterant catalytic properties. Finally, fermentation for keratinase production in a 15 L fermenter was carried out, and the enzyme activity reached up to over 3000 units/mL. Our results demonstrated that pro-peptide engineering played a crucial role in high expression and engineering of proteases. This study provides a universal route toward improvement of industrial enzymes that were first synthesized as precursors in the form of pre-pro-protein.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acssynbio.8b00442 | DOI Listing |
Nanotechnol Sci Appl
February 2025
Department of Biotechnology & Genetic Engineering, Kohat University of Science & Technology, Kohat, Pakistan.
Introduction: Immobilizing enzymes on solid supports such as magnetic nanoparticles offers multi-dimensional advantages, including enhanced conformational, structural, and thermal stability for long-term storage and reusability.
Methodology: The gene encoding subtilisin Carlsberg was isolated from proteolytic , a bacterium derived from salt mines. The nucleotide sequence encoding pro-peptide and mature protein were cloned into pET22(a)+ vector and expressed in .
Tissue Cell
April 2025
Department of Chemistry and Biochemistry, Faculty of Medicine and Pharmacy, Ibn Zohr University, Laayoune 70000, Morocco.
Bifenthrin (BFN) is a noxious insecticide which is reported to damage various body organs. Daidzein (DZN) is a natural flavone with excellent pharmacological properties. This research was conducted to evaluate the alleviative strength of DZN to counteract BFN prompted liver toxicity in male albino rats.
View Article and Find Full Text PDFBiomaterials
June 2025
Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu, 610031, PR China.
Astrocytes can be reacted to "reactive astrocytes" after ischemia-reperfusion injury, in which A1 phenotype causes neuronal and oligodendrocyte death, whereas the A2 phenotype exerts neuroprotective effects, thus regulating reactive astrocyte to A2 type is a potential target for stroke therapy. Lcn2 level is highly associated with the phenotypic polarization of astrocytes. We found that silencing the Lcn2 gene by adeno-associated virus (AAV)-Lcn2 shRNA adenovirus resulted in a dramatic decrease in A1-type astrocytes and increase in A2 astrocytes in MCAO mice.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Dompé Farmaceutici S.p.A., Via Campo di Pile, Nucleo Industriale Pile, 67100 L'Aquila, Italy.
Thus far, no manufacturing process able to support industrialization has been reported for the recombinant human brain-derived neurotrophic factor (rhBDNF). Here, we described the setup of a new protocol for its production in () and its purification to homogeneity. A synthetic gene, codifying for the neurotrophin precursor, was inserted into an expression vector and transformed into BL21 (DE3) strain.
View Article and Find Full Text PDFJBMR Plus
December 2024
Center for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME 04074, United States.
Canagliflozin (CANA) is a sodium glucose cotransporter-2 inhibitor that reduces blood glucose levels. Sodium glucose cotransporter-2 is primarily expressed in the kidney, but not in any bone cells, therefore effects on the skeleton are likely to be non-cell autonomous. Originally developed to treat type II diabetes, CANA use has expanded to treat cardiovascular and renovascular disease.
View Article and Find Full Text PDF